Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Alagebrium (ALT-711) and SLU-PP-332 — mechanism, side effects, legal status, and pricing.
Alagebrium (ALT-711) is a thiazolium-derived non-peptide small molecule investigated as an advanced glycation end-product (AGE) crosslink breaker. It reached Phase I–III human trials (2001–2010) for diastolic heart failure and hypertension but was never approved; clinical development was discontinued around 2009 due to financial constraints. No validated human dose exists. Currently sold by research-chemical vendors for research use only.
SLU-PP-332 is a small-molecule (non-peptide) pan-agonist of estrogen-related receptors ERRα/β/γ developed at Saint Louis University. Studied preclinically as an exercise mimetic in rodents, it has no human clinical data and is NOT FDA-approved. Sold only as a grey-market research chemical.
Alagebrium (ALT-711)
SLU-PP-332
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Alagebrium (ALT-711)
SLU-PP-332
COA corpus from Disclosed Labs — independently tested batches only.
Alagebrium (ALT-711)
2
COAs
99.6%
Avg purity
2
Labs
SLU-PP-332
26
COAs
99.5%
Avg purity
11
Labs
Alagebrium reached Phase I–III human trials (2001–2010) under sponsor Alteon Inc./Synvista Therapeutics but was never approved. A 16-week open-label pilot in 23 elderly patients (21 completers) with diastolic heart failure showed reduced left ventricular mass and improved Doppler diastolic index (E') without change in blood pressure, ejection fraction, or exercise capacity. The SPECTRA trial (ALT-711 + hydrochlorothiazide in hypertension) was terminated; the BENEFICIAL trial (chronic heart failure) was completed but did not meet efficacy endpoints. Preclinical studies in non-diabetic hypertensive rats, aged dogs, aged monkeys, streptozotocin-induced diabetic rats, and diabetic mouse models demonstrated improved vascular/cardiac function, reduced aortic stiffness, decreased collagen crosslinking, and improved renal pathology. A 2-year rat toxicology study found liver alterations that prompted a temporary enrollment suspension pending review.
Billon et al. (ACS Chemical Biology, 2023) reported that SLU-PP-332 in sedentary mice increased treadmill endurance, enhanced slow-twitch fiber content, boosted mitochondrial biogenesis, and conferred resistance to high-fat-diet weight gain without exercise training. A follow-up (Billon et al., J Pharmacol Exp Ther, 2024) showed benefits in mouse metabolic-syndrome models. Developed at Saint Louis University (Burris/Walker/Elgendy groups). Rodent/preclinical data ONLY — no human clinical trials have been initiated. Not FDA-approved; not a peptide.
Alagebrium (ALT-711) and SLU-PP-332 are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs